Thrombin-Anti-Thrombin Levels and Patency of Arterio-Venous Fistula in Patients Undergoing Haemodialysis Compared to Healthy Volunteers: A Prospective Analysis

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Milburn, James A ^a   Ford, Isobel ^b   Mutch, Nicola J ^b   Fluck, Nicholas ^a   Brittenden, Julie ^b  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; C REACTIVE PROTEIN; D DIMER; HEPARIN; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; SURVIVAL; VASCULAR ACCESS; VASCULAR PATENCY; VENOUS BLOOD;

ADULT; AGED; AGED, 80 AND OVER; ANTITHROMBIN PROTEINS; ARTERIOVENOUS FISTULA; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FOLLOW-UP STUDIES; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; P-SELECTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES; RENAL DIALYSIS; THROMBIN; TIME FACTORS; VASCULAR PATENCY; VON WILLEBRAND FACTOR; YOUNG ADULT;

FISTULA;

EID: 84879778364     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067799     Document Type: Article

References (40)

1. Covic A, Gusbeth-Tatomir P, Goldsmith DJ, (2003) The challenge of cardiovascular risk factors in end-stage renal disease. J Nephrol 16: 476-486. PubMed: 14696749.
2. Huijbregts HJ, Bots ML, Wittens CH, Schrama YC, Moll FL, et al. (2008) Hemodialysis arteriovenous fistula patency revisited: results of a prospective, multicenter initiative. Clin J Am Soc Nephrol 3: 714-719. doi:10.2215/CJN.02950707. PubMed: 18256379.
3. Feldman HI, Kobrin S, Wasserstein A, (1996) Hemodialysis vascular access morbidity. J Am Soc Nephrol 7: 523-535. PubMed: 8724885.
4. Hakim R, Himmelfarb J, (1998) Hemodialysis access failure: a call to action. Kidney Int 54: 1029-1040. doi:10.1046/j.1523-1755.1998.00122.x. PubMed: 9767519.
5. Darlington A, Ferreiro JL, Ueno M, Suzuki Y, Desai B, et al. (2011) Haemostatic profiles assessed by thromboelastography in patients with end-stage renal disease. Thromb Haemost 106: 67-74. doi:10.1160/TH10-12-0785. PubMed: 21655674.
6. Bartels PC, Schoorl M, Schoorl M, Wiering JG, Nubé MJ, (2000) Activation of coagulation during treatment with haemodialysis. Scand J Clin Lab Invest 60: 283-290. doi:10.1080/003655100750046440. PubMed: 10943598.
7. Sagedal S, Hartmann A, Sundstrøm K, Bjørnsen S, Brosstad F, (2001) Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant 16: 987-993. doi:10.1093/ndt/16.5.987. PubMed: 11328905.
8. Malyszko J, Malyszko JS, Pawlak D, Pawlak K, Buczko W, et al. (1996) Hemostasis, platelet function and serotonin in acute and chronic renal failure. Thromb Res 83: 351-361. doi:10.1016/0049-3848(96)00145-4. PubMed: 8873344.
9. Al-Saady NM, Leatham EW, Gupta S, Kwan JT, Eastwood JB, et al. (1999) Monocyte expression of tissue factor and adhesion molecules: the link with accelerated coronary artery disease in patients with chronic renal failure. Heart 81: 134-140. PubMed: 9922347.
10. Milburn JA, Cassar K, Ford I, Fluck N, Brittenden J, (2011) Prothrombotic changes in platelet, endothelial and coagulation function following hemodialysis. Int J Artif Organs 34: 280-287. doi:10.5301/IJAO.2011.6469. PubMed: 21445833.
11. Erdem Y, Haznedaroglu IC, Celik I, Yalcin AU, Yasavul U, et al. (1996) Coagulation, fibrinolysis and fibrinolysis inhibitors in haemodialysis patients: contribution of arteriovenous fistula. Nephrol Dial Transplant 11: 1299-1305. doi:10.1093/oxfordjournals.ndt.a027542. PubMed: 8672026.
12. Oda H, Ohno M, Ohashi H, (2000) Coagulation and fibrinolysis factors in dialysis patients with and without ischemic heart disease. Adv Perit Dial 16: 152-155. PubMed: 11045282.
13. Kirmizis D, Tsiandoulas A, Pangalou M, Koutoupa E, Rozi P, et al. (2006) Validity of plasma fibrinogen, D-dimer, and the von Willebrand factor as markers of cardiovascular morbidity in patients on chronic hemodialysis. Med Sci Monit 12: R55-R62. PubMed: 16449948.
14. Casserly LF, Dember LM, (2003) Thrombosis in end-stage renal disease. Semin Dial 16: 245-256. doi:10.1046/j.1525-139X.2003.16048.x. PubMed: 12753687.
15. Haznedaroǧlu IC, Erdem Y, Celik I, Sayinalp NM, Dündar SV, et al. (1996) Local fibrinolysis in native arteriovenous fistulas of haemodialysis patients. Blood Purif 14: 227-233. doi:10.1159/000170265. PubMed: 8738536.
16. Pawlak K, Pawlak D, Mysliwiec M, (2007) Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity. Thromb Res 119: 475-480. doi:10.1016/j.thromres.2006.03.011. PubMed: 16828495.
17. Salobir B, Sabovic M, Zupan IP, Ponikvar JB, (2008) Platelet (dys)function and plasma plasminogen levels in hemodialysis patients. Ther Apher Dial 12: 133-136. doi:10.1111/j.1744-9987.2008.00558.x. PubMed: 18387161.
18. Trimarchi H, Duboscq C, Genoud V, Lombi F, Muryan A, et al. (2008) Plasminogen activator inhibitor-1 activity and 4G/5G polymorphism in hemodialysis. J Vasc Access 9: 142-147. PubMed: 18609532.
19. D'Elia JA, Weinrauch LA, Gleason RE, Lipinska I, Lipinski B, et al. (2005) Risk factors for thromboembolic events in renal failure. Int J Cardiol 101: 19-25. doi:10.1016/j.ijcard.2004.03.007. PubMed: 15860378.
20. Borawski J, Naumnik B, Pawlak K, Mysliwiec M, (2001) Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response. Nephrol Dial Transplant 16: 1442-1447. doi:10.1093/ndt/16.7.1442. PubMed: 11427638.
21. Inoue A, Wada H, Takagi M, Yamamuro M, Mukai K, et al. (2000) Hemostatic abnormalities in patients with thrombotic complications on maintenance hemodialysis. Clin Appl Thromb Hemost 6: 100-103. doi:10.1177/107602960000600210. PubMed: 10775031.
22. Sioulis A, Malindretos P, Makedou A, Makris P, Grekas D, (2009) Coagulation factors as biological risk markers of endothelial dysfunction. Association with the thrombotic episodes of chronic hemodialysis patients. Hippokratia 13: 237-241. PubMed: 20011089.
23. Sidawy AN, Gray R, Besarab A, Henry M, Ascher E, et al. (2002) Recommended standards for reports dealing with arteriovenous hemodialysis accesses. J Vasc Surg 35: 603-610. doi:10.1067/mva.2002.122025. PubMed: 11877717.
24. Milburn JA, Ford I, Cassar K, Fluck N, Brittenden J, (2012) Platelet activation, coagulation activation and C-reactive protein in simultaneous samples from the vascular access and peripheral veins of haemodialysis patients. Int J Lab Hematol 34: 52-58. doi:10.1111/j.1751-553X.2011.01356.x. PubMed: 21722325.
25. Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR, (1988) Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 70: 327-333. doi:10.1111/j.1365-2141.1988.tb02490.x. PubMed: 3264718.
26. Greaves M, Pickering C, Knight G, Boulton AJ, Ball J, et al. (1987) Changes in the factor VIII complex in diabetic ketoacidosis: evidence of endothelial cell damage? Diabetologia 30: 160-165. doi:10.1007/BF00274221. PubMed: 3108060.
27. Sadosty AT, Goyal DG, Boie ET, Chiu CK, (2001) Emergency department D-dimer testing. J Emerg Med 21: 423-429. doi:10.1016/S0736-4679(01)00408-5. PubMed: 11728773.
28. Gyöngyösi M, Glogar D, Weidinger F, Domanovits H, Laggner A, et al. (2004) Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-ST-segment elevation myocardial infarction. AM Hear J 147: 158-164. doi:10.1016/j.ahj.2003.07.015. PubMed: 14691435.
29. Segarra A, Chacón P, Martinez-Eyarre C, Argelaguer X, Vila J, et al. (2001) Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator and thrombomodulin in hemodialysis patients: biochemical correlations and role as independent predictors of coronary artery stenosis. J Am Soc Nephrol 12: 1255-1263. PubMed: 11373350.
30. Stolic RV, Trajkovic GZ, Peric VM, Jovanovic AN, Markovic SR, et al. (2008) The influence of atherosclerosis and plasma D-dimer concentration in patients with a functioning arteriovenous fistula for maintenance hemodialysis. Int Urol Nephrol 40: 503-508. doi:10.1007/s11255-007-9321-8. PubMed: 18228158.
31. De Marchi S, Falleti E, Giacomello R, Stel G, Cecchin E, et al. (1996) Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients. J Am Soc Nephrol 7: 1169-1177. PubMed: 8866409.
32. Casonato A, Pontara E, Vertolli UP, Steffan A, Durante C, et al. (2001) Plasma and platelet von Willebrand factor abnormalities in patients with uremia: lack of correlation with uremic bleeding. Clin Appl Thromb Hemost 7: 81-86. doi:10.1177/107602960100700201. PubMed: 11292197.
33. Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA, (1999) Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive. Thromb Haemost 82: 1456-1461. PubMed: 10595638.
34. Paffen E, DeMaat MP, (2006) C-reactive protein in atherosclerosis: A causal factor? Cardiovasc Res 71: 30-39. doi:10.1016/j.cardiores.2006.03.004. PubMed: 16624260.
35. Chou CY, Kuo HL, Yung YF, Liu YL, Huang CC, (2006) C-reactive protein predicts vascular access thrombosis in hemodialysis patients. Blood Purif 24: 342-346. doi:10.1159/000092558. PubMed: 16601326.
36. Bisoendial RJ, Boekholdt SM, Vergeer M, Stroes ES, Kastelein JJ, (2010) C-reactive Protein is a mediator of cardiovascular disease. Eur Heart J 31: 2087-2091. doi:10.1093/eurheartj/ehq238. PubMed: 20685682.
37. Hutchinson WL, Koenig W, Fröhlich M, Sund M, Lowe GD, et al. (2000) Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem 46: 934-938. PubMed: 10894836.
38. Osborn G, Escofet X, Da Silva A, (2008) Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database Syst Rev. 4: 002786. PubMed: 18843633.
39. Rao AK, Vaidyula VR, Bagga S, Jalagadugula G, Gaughan J, et al. (2006) Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease. Thromb Haemost 96: 738-743. PubMed: 17139367.
40. Müller I, Massberg S, Zierhut W, Binz C, Schuster A, et al. (2002) Effects of aspirin and clopidogrel versus oral anticoagulation on platelet function and on coagulation in patients with nonvalvular atrial fibrillation (CLAFIB). Pathophysiol Haemost Thromb 32: 16-24. doi:10.1159/000057284. PubMed: 12214159.